Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.
Galecto has raised $275.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in February 2026.
Galecto's investors include Andreessen Horowitz, RA Capital Management, Wellington Management, Janus Henderson Investors, Balyasny Asset Management.
Galecto is headquartered in Copenhagen, Denmark.
Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.
Galecto is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Galecto — Funding & Investors." VCBacked, February 10, 2026, https://www.vcbacked.co/company/galecto. Accessed November 12, 2026.
VCBacked. (2026). Galecto — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/galecto
{{cite web |title=Galecto — Funding & Investors |url=https://www.vcbacked.co/company/galecto |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Galecto? Request a listing update